Paul Lander

Title: **Innovator Spotlight: Paul Lander**

Introduction

Paul Lander, an inventive mind based in Norman, OK, has made significant contributions to the field of medical technology, particularly in electrocardiogram (ECG) analysis. With three patents to his name, Lander is a respected figure in the domain of heart health diagnostics through innovative signal processing techniques.

Latest Patents

Lander's most recent patents focus on the advanced analysis of electrocardiogram signals. One of his notable inventions is a method and apparatus for bi-spectral filtering of ECG signals. This technology allows for thorough scrutiny of heart activity by utilizing orthogonal x, y, and z input signals. The signals are processed to identify QRS onset and offset, employing spectral filters with specific passbands. This innovation ensures accurate determinations of RMS voltage values and low amplitude signals, which are crucial for evaluating heart defects and abnormalities.

Another significant patent by Lander is centered on the analysis and interpretation of ECG signal data for diagnostic applications. By implementing an incrementally moving, short window Fast Fourier Transform (FFT) analysis, his methodology produces spectral templates that encapsulate the frequency content of the ECG during different window positions. The ability to visualize these templates as three-dimensional surfaces enables a deeper understanding of the heart's performance and its potential abnormalities.

Career Highlights

Paul Lander is currently employed at Corazonix Corporation, where he applies his expertise in signal processing and ECG analysis to further develop innovative technologies in the medical field. His commitment to improving heart diagnostics positions him as a key contributor to advancements in cardiac health technology.

Collaborations

In his professional journey, Lander collaborates closely with David E. Albert, leveraging their combined expertise to push the boundaries of what's possible in ECG analysis. This partnership enhances the development of technologies aimed at diagnosing heart conditions more effectively and efficiently.

Conclusion

Paul Lander's contributions to the field of electrocardiogram analysis through his patented innovations not only mark significant milestones in medical technology but also promise advancements that can lead to improved patient outcomes. As he continues to work at Corazonix Corporation, the future of ECG diagnostics looks brighter with his dedication to innovation.